Article

Model evaluates risk assessment for ectasia after LASIK

Investigators at Emory University, Atlanta, have developed a comprehensive weighted risk factor scale that should significantly improve the identification of eyes at high risk for development of corneal ectasia following LASIK. J. Bradley Randelman, MD, assistant professor of ophthalmology, section of cornea, external disease, and refractive surgery at Emory University, along with several colleagues, devised the model after conducting a retrospective review of all ectasia cases seen at Emory and reported in the literature. They found 171 cases and compared them with 186 controls.

Investigators at Emory University, Atlanta, have developed a comprehensive weighted risk factor scalethat should significantly improve the identification of eyes at high risk for development of cornealectasia following LASIK. J. Bradley Randleman, MD, assistant professor of ophthalmology, section ofcornea, external disease, and refractive surgery at Emory University, along with several colleagues,devised the model after conducting a retrospective review of all ectasia cases seen at Emory andreported in the literature. They found 171 cases and compared them with 186 controls.

Topographic patterns were classified as normal or symmetrical, suspicious, or abnormal. Theinvestigators found significant differences between patients with ectasia and the controls for all ofthe variables they assessed. Patients with ectasia were younger, more myopic, had thinner corneaspreoperatively, had a higher percentage of abnormal topographies, and had significantly thinnerresidual stromal beds. Investigators also analyzed a subgroup of patients and controls for whom theyhad all available information and found similar differences between them.

From this subgroup they determined that the most important risk factors, in order, were abnormaltopography, residual stromal bed, age, and preoperative corneal thickness. This information was usedto develop a risk modeling system in which each risk factor was given a weighted point value. In thescoring system, 0 to 2 was low risk, a level at which it was safe to proceed with LASIK, and 3 wasmoderate risk, meriting a cautious approach to LASIK and consideration of other options. A score of 4or above was high risk, a level at which LASIK should not be performed.

Applying this scoring system to their study groups, the investigators found that 98% of the controlpopulation was identified as low risk and 93% of the patients with ectasia were identified as highrisk. They would not have been offered surgery based on this model, Dr. Randleman said.

He pointed out, however, that eyes with no known risk factors can develop ectasia and that patientswho have one or more risk factors will not necessarily have postoperative complications. Dr. Randleman'spresentation was selected as the best of the refractive free papers session.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.